ClinicalTrials.gg
CompletedNCT03309878Updated Sep 21, 2023Results posted

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

A Phase 1/2 interventional study of Mogamulizumab and Pembrolizumab in Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma and Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, sponsored by National Cancer Institute (NCI). Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-14

Among 128 studies in Lymphoma, Large B-Cell, Diffuse by National Cancer Institute (NCI) — 8 open to participants now, 18 under way, 3 of them phase 3. Lymphoma, Large B-Cell, Diffuse · National Cancer Institute (NCI).

Enrollment
113th of 119
8 · median 36
Started
2018
with 4 others
Phase 1/2
11 of 128
1 open now
Registered
114th of 128
by date

Among the 128 studies in Lymphoma, Large B-Cell, Diffuse by National Cancer Institute (NCI), this one is the 113th largest by enrollment of the 119 interventional ones that give a count, is one of 5 that started in 2018, is one of 11 in phase 1/2, and was the 114th registered.

Lymphoma, Large B-Cell, Diffuse

1,870 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

8 of the 128 studies in Lymphoma, Large B-Cell, Diffuse by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Lymphoma, Large B-Cell, Diffuse by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase I/II trial studies the best dose and side effects of mogamulizumab in combination with pembrolizumab and to see how well they work in treating patients with diffuse large B cell lymphoma that have come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as mogamulizumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of KW-0761 (mogamulizumab) when administered in combination with MK-3475 (pembrolizumab) in patients with relapsed, refractory diffuse large B-cell lymphoma. (Phase I) II. To assess the safety and tolerability of KW-0761 (mogamulizumab) when administered in combination with MK-3475 (pembrolizumab) in patients with relapsed, refractory diffuse large B-cell lymphoma. (Phase I) III. To assess the progression-free survival of KW-0761 (mogamulizumab) when administered in combination with MK-3475 (pembrolizumab) compared to MK-3475 (pembrolizumab) alone in patients with relapsed and refractory diffuse large B-cell lymphomas. (Phase II)

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. (Phase I) II. To assess the overall response rate, complete response rate, partial response rate, duration of response of KW-0761 (mogamulizumab) and MK-3475 (pembrolizumab) compared to MK-3475 (pembrolizumab) alone in patients with relapsed and refractory diffuse large B-cell lymphomas. (Phase II)

EXPLORATORY OBJECTIVES:

I. To determine whether the progression-free survival of KW-0761 (mogamulizumab) and MK-3475 (pembrolizumab) when administered to patients with relapsed and refractory diffuse large B-cell lymphomas differs based on the presence or absence of mutations in B2M or CD58 or amplifications in PD-L1.

II. To determine whether the progression-free survival of KW-0761 (mogamulizumab) and MK-3475 (pembrolizumab) when administered to patients with relapsed and refractory diffuse large B-cell lymphomas differs based on changes in CD8 T-cell, natural killer (NK) cell, and FoxP3+ regulatory T cell (Treg) prevalence in response to therapy as measured by immunohistochemistry.

III. To determine whether KW-0761 (mogamulizumab) and MK-3475 (pembrolizumab) alters the prevalence of peripheral blood CCR4+/FoxP3+ regulatory T-cells as well as effector CD4 and CD8 T-cells by multi-parametric flow cytometry.

OUTLINE: This is a phase I, dose-escalation study of mogamulizumab followed by a phase II study. Patients are randomized to 1 of 2 arms.

ARM I: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and mogamulizumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, then day 1 of subsequent courses. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.

03

Conditions studied

  • Recurrent Diffuse Large B-Cell Lymphoma
  • Recurrent High Grade B-Cell Lymphoma
  • Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Refractory High Grade B-Cell Lymphoma
  • Refractory Transformed B-Cell Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have confirmed diffuse large B-cell lymphoma; all subtypes of diffuse large B-cell lymphoma are eligible, including high-grade B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL) that has transformed from a prior indolent B-cell non-Hodgkin lymphoma
  • Patients must have per 2014 Lugano Classification Criteria which is defined as at least one nodal lesion measuring > 1.5 cm in greatest diameter or at least one extranodal lesion measuring > 1.0 cm in greatest diameter
  • For phase 2: patients and received at least 2 and must have previously received, refused, or been deemed ineligible for stem cell transplantation
  • (ECOG) performance status =\< 1 ( >= 80%)
  • >= 1,500/mcL (if neutropenia is related to bone marrow involvement with lymphoma, the absolute neutrophil count must be >= 1,000/mcL)
  • >= 75,000/mcL (if thrombocytopenia is related to bone marrow involvement with lymphoma, the platelet count must be >= 50,000/mcL)
  • >= 9 g/dL (if anemia is related to bone marrow involvement with lymphoma, the hemoglobin must be >= 8 g/dL)
  • Total =\< 1.5 x the institutional (ULN) or \< 3 x the ULN for indirect bilirubin in patients with Gilbert's disease
  • (AST) and alanine aminotransferase (ALT) =\< 2.5 x institutional upper limit of normal
  • Creatinine =\< 1.5 x institutional upper limit of normal OR measured or calculated if creatinine > 1.5 x ULN then creatinine clearance >= 40 mL/min/1.73 m\^2 as calculated by Cockcroft and Gault equation
  • of greater than 3 months
  • The effects of MK-3475 (pembrolizumab) in combination with KW-0761 (mogamulizumab) on the developing human fetus are unknown; for this reason, women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and 6 months after completion of MK-3475 (pembrolizumab) in combination with KW-0761 (mogamulizumab) administration; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of MK-3475 (pembrolizumab) in combination with KW-0761 (mogamulizumab) administration
  • Submit adequate specimen (25+ unstained slides or 2 tissue blocks) from a biopsy performed after progression of disease on most recent therapy OR subject is willing to undergo a new core or excisional biopsy to obtain evaluable tumor tissue sample for immunohistochemical assessment and sequencing for B2M loss; repeat samples may be required if adequate tissue is not provided, however, patients may still be considered for enrollment on a case by case basis following consultation with the principal investigator (PI)
  • Ability to understand and the willingness to sign a written document
  • Subjects with prior history of chemotherapy-induced or radiation-induced pulmonary toxicity require confirmation of diffuse capacity of the lung for carbon monoxide (DLCO) over 60% (adjusted for hemoglobin) by a pulmonary function test prior to study enrollment

Exclusion criteria

Exclusion Criteria:

  • Patients who have had previous systemic anti-cancer therapy within 3 weeks of registration or those who have not recovered from adverse events due to agents administered previously

    • Note: Patients are considered enrolled on the study after protocol registration and not after signing consent
  • Patients who are receiving any other concurrent agents
  • Patient is receiving systemic therapy or any other form of therapy within 7 days prior to the first dose of trial treatment; the use of physiologic doses of corticosteroids (e.g. prednisone =\< 20 mg/d) may be approved after consultation with the study PI; topical or inhaled corticosteroids are allowed
  • Has a known additional that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer
  • Patients with active cerebral or meningeal involvement by lymphoma should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound evaluation of neurologic and other adverse events
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab) or KW-0761 (mogamulizumab)
  • Subject with active disease; subjects with vitiligo, eczema, alopecia, type I diabetes mellitus, psoriasis not requiring systemic treatment, or endocrine deficiencies (such as hypothyroidism) managed with replacement hormones, including physiologic corticosteroid replacement therapy are eligible
  • Has a history or currently active (non-infectious) pneumonitis that required steroids unless prior history of chemotherapy or radiotherapy induced pneumonitis meeting the eligibility criteria
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator
  • Has received prior therapy with an , anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
  • Prior stem cell transplant (SCT)
  • Patients who are planning to receive allogeneic SCT in the near future as preliminary reports suggest added toxicity in patients undergoing allogeneic stem cell transplantation after having received mogamulizumab
  • Autologous SCT =\< 90 days prior to first dose of study drug
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because MK-3475 (pembrolizumab) is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MK-3475 (pembrolizumab), breastfeeding should be discontinued if the mother is treated with MK-3475 (pembrolizumab); these potential risks may also apply to KW-0761 (mogamulizumab)
  • MK-3475 (pembrolizumab) and KW-0761 (mogamulizumab) may have adverse effects on a fetus in utero; furthermore, it is not known if MK-3475 (pembrolizumab) or KW-0761 (mogamulizumab) has transient adverse effects on the composition of sperm; patients are excluded from this study if pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of trial treatment
  • Patients with (HIV) are excluded if they have a detectable viral load, are not on a stable antiretroviral regimen, have a decreased (\< 500), or require prophylactic antibiotics for the prevention of opportunistic infections
  • Has a known history of (defined as hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection

    • Note: No testing for hepatitis B and hepatitis C is required unless mandated by local health authority
  • Has a known history of active tuberculosis (TB)
  • Patients with significant cardiac disease (e.g., [NYHA] class III-IV congestive heart failure, unstable angina, recent myocardial infarction within the last 6 months, etc.)
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Arm I (pembrolizumab, mogamulizumab)

    Patients receive pembrolizumab IV over 30 minutes on day 1 and mogamulizumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, then day 1 of subsequent courses. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

    Biological: Mogamulizumab · Biological: Pembrolizumab

  • Experimental
    Arm II (pembrolizumab)

    Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

    Biological: Pembrolizumab

Interventions

  • BiologicalMogamulizumab

    Given IV

    Also known as: Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer, KM8761, KW-0761, Mogamulizumab-kpkc, Poteligeo

  • BiologicalPembrolizumab

    Given IV

    Also known as: BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) of Mogamulizumab in Combination With Pembrolizumab (Phase I)

    Will be determined by dose limiting toxicity (DLT). A standard 3+3 design will be used to find the MTD or RP2D for the combination of pembrolizumab and mogamulizumab.

    Time frame: Up to 6 weeks

  2. Incidence of Adverse Events (Phase I)

    Number of incidences of grade 3-5 adverse events at least possibly related to the study intervention will be reported. Adverse events will be graded according to Common Terminology Criteria for Adverse Events version 4.03 (Version 5.0 beginning April 1, 2018).

    Time frame: Up to 25 months

  3. Progression-free Survival (PFS) (Phase II)

    The Kaplan Meier method will be used to estimate the median PFS.

    Time frame: From course 1 day 1 to the first date of recurrence, progression, or death due to any cause, whichever comes first, assessed up to 12 months

Secondary outcomes

  1. Overall Response Rate

    Will be calculated along with exact 95% confidence intervals.

    Time frame: Up to 25 months

  2. Complete Response Rate

    Will be calculated along with exact 95% confidence intervals.

    Time frame: Up to 25 months

  3. Partial Response Rate

    Will be calculated along with exact 95% confidence intervals.

    Time frame: Up to 25 months

  4. Duration of Response

    Will be summarized by Kaplan-Meier method in patients who achieve complete response (CR) or partial response (PR).

    Time frame: Up to 25 months

Other outcomes

  1. Biomarker Analysis

    Performed and summarized using descriptive statistics and graphical displays at pre and post treatment time points.

    Time frame: Up to 25 months

07

Results

Posted Jun 7, 2023

Participant flow

Participant flow — Overall Study
MilestonePhase I Dose Level 1Phase I Dose Level -1Phase II Arm APhase II Arm B
Started4400
Completed1200
Not completed3200
Withdrew: Adverse event1000
Withdrew: Did not maintain eligibility2100
Withdrew: Withdrawal by subject0100

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) of Mogamulizumab in Combination With Pembrolizumab (Phase I)

Will be determined by dose limiting toxicity (DLT). A standard 3+3 design will be used to find the MTD or RP2D for the combination of pembrolizumab and mogamulizumab.

Time frame:
Up to 6 weeks
Reported as:
Count of participants · Participants
Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) of Mogamulizumab in Combination With Pembrolizumab (Phase I)
ParticipantsPhase I Dose Level 1Phase I Dose Level -1
Dose limiting toxicity occurred01
Dose limiting toxicity did not occur20
PrimaryIncidence of Adverse Events (Phase I)

Number of incidences of grade 3-5 adverse events at least possibly related to the study intervention will be reported. Adverse events will be graded according to Common Terminology Criteria for Adverse Events version 4.03 (Version 5.0 beginning April 1, 2018).

Time frame:
Up to 25 months
Reported as:
Number · Related Incidences
Incidence of Adverse Events (Phase I)
Related IncidencesPhase I Dose Level 1Phase I Dose Level -1
Experienced Grade 3 Adverse Events40
Experienced Grade 4 Adverse Events50
Experienced Grade 5 Adverse Events01
PrimaryProgression-free Survival (PFS) (Phase II)

The Kaplan Meier method will be used to estimate the median PFS.

Time frame:
From course 1 day 1 to the first date of recurrence, progression, or death due to any cause, whichever comes first, assessed up to 12 months

No measurements were reported for this outcome.

SecondaryOverall Response Rate

Will be calculated along with exact 95% confidence intervals.

Time frame:
Up to 25 months
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsPhase I Dose Level 1Phase I Dose Level -1Phase II Arm APhase II Arm B
Experienced Complete Response00——
Experienced Partial Response00——
Experienced Stable Disease00——
Experienced Disease Progression11——
Not evaluated10——
SecondaryComplete Response Rate

Will be calculated along with exact 95% confidence intervals.

Time frame:
Up to 25 months
Reported as:
Count of participants · Participants
Complete Response Rate
ParticipantsPhase I Dose Level 1Phase I Dose Level -1Phase II Arm APhase II Arm B
Complete Response Rate0000
SecondaryPartial Response Rate

Will be calculated along with exact 95% confidence intervals.

Time frame:
Up to 25 months
Reported as:
Count of participants · Participants
Partial Response Rate
ParticipantsPhase I Dose Level 1Phase I Dose Level -1Phase II Arm APhase II Arm B
Partial Response Rate0000
SecondaryDuration of Response

Will be summarized by Kaplan-Meier method in patients who achieve complete response (CR) or partial response (PR).

Time frame:
Up to 25 months

No measurements were reported for this outcome.

Other pre-specifiedBiomarker Analysis

Performed and summarized using descriptive statistics and graphical displays at pre and post treatment time points.

Time frame:
Up to 25 months

No measurements were reported for this outcome.

Adverse events

Collected over Up to 25 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I Dose Level 10/2 (0%)2/2 (100%)2/2 (100%)
Phase I Dose Level -11/1 (100%)1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventPhase I Dose Level 1Phase I Dose Level -1
AcidosisMetabolism and nutrition disorders0/21/1
HypercalcemiaMetabolism and nutrition disorders1/20/1
Heart failureCardiac disorders1/20/1
ColitisGastrointestinal disorders1/20/1
DehydrationMetabolism and nutrition disorders1/20/1
Infusion-related reactionInjury, poisoning and procedural complications1/20/1
Ejection fraction decreasedInvestigations1/20/1
AnemiaBlood and lymphatic system disorders1/20/1
Apical ballooningCardiac disorders1/20/1
HypotensionVascular disorders1/20/1
Most frequent other events
Showing 10 of 52
Most frequent other events
EventPhase I Dose Level 1Phase I Dose Level -1
AnemiaBlood and lymphatic system disorders2/20/1
AnorexiaMetabolism and nutrition disorders2/20/1
Aspartate aminotransferase increasedInvestigations1/21/1
CoughRespiratory, thoracic and mediastinal disorders2/20/1
AcidosisMetabolism and nutrition disorders0/21/1
Alanine aminotransferase increasedInvestigations0/21/1
Alkaline phosphatase increasedInvestigations0/21/1
Electrocardiogram QT corrected interval prolongedInvestigations2/20/1
FatigueGeneral disorders2/20/1
FeverGeneral disorders2/20/1

Baseline characteristics

No enrollments to Phase II

Age, Continuous
Age, Continuous(years)Phase I Dose Level 1Phase I Dose Level -1Phase II Arm APhase II Arm BTotal
Median71.5 (55 to 80)55.5 (50 to 77)——64.5 (50 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Phase I Dose Level 1Phase I Dose Level -1Phase II Arm APhase II Arm BTotal
Female10——1
Male34——7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase I Dose Level 1Phase I Dose Level -1Phase II Arm APhase II Arm BTotal
Hispanic or Latino00——0
Not Hispanic or Latino34——7
Unknown or Not Reported10——1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I Dose Level 1Phase I Dose Level -1Phase II Arm APhase II Arm BTotal
American Indian or Alaska Native00——0
Asian00——0
Native Hawaiian or Other Pacific Islander00——0
Black or African American01——1
White33——6
More than one race00——0
Unknown or Not Reported10——1
Region of Enrollment
Region of Enrollment(participants)Phase I Dose Level 1Phase I Dose Level -1Phase II Arm APhase II Arm BTotal
United States44——8
08

Study locations

8 sites
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • Memorial Sloan Kettering Monmouth
    Middletown, New Jersey 07748, United States
  • Memorial Sloan Kettering Bergen
    Montvale, New Jersey 07645, United States
  • Memorial Sloan Kettering Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Westchester
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Nassau
    Uniondale, New York 11553, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jan 2021, 26 months.

Results were first posted in Jun 2023, 2 years 5 months after primary completion.

Of 57 non-industry phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 94. This study's 26 months is below that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2017
First posted
Oct 16, 2017
StartActual
Oct 24, 2018
Primary completionActual
Jan 6, 2021
CompletionActual
Apr 11, 2023
Results first posted
Jun 7, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03309878
Responsible party
Sponsor
First posted
Oct 16, 2017
Start date
Oct 24, 2018
Primary completion
Jan 6, 2021
Completion
Apr 11, 2023
Results posted
Jun 7, 2023
Last update
Sep 21, 2023

Study contacts

Erel Joffe
principal investigator · JHU Sidney Kimmel Comprehensive Cancer Center LAO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mogamulizumab

Start the discussion